Monday 29 February 2016

Global Cervical Cancer Market Structure And Report to 2019

Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma.

Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups.

Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer. Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue.

Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas. The report analysts forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.

Covered in this Report:

The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.

Global Cervical Cancer Market has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

To Read more reports of this category:
http://www.radiantinsights.com/catalog/pharmaceutical

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
Other Prominent Vendors
  • Advaxis Immunotherapies
  • Bionor Pharma
  • Dendreon Corporation
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • Otsuka Pharmaceuticals
  • Profectus Biosciences
  • Virometix
  • Zeria Pharmaceuticals
Key Market Driver
  • Increase in incidence rate
  • For a full, detailed list, view our report
Key Market Challenge
  • Adverse effects of drugs and vaccines
  • For a full, detailed list, view our report
Key market trend
  • Patient assistance programs
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

No comments:

Post a Comment